➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
Moodys
McKinsey
Johnson and Johnson

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Patent: 10,590,182

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,590,182
Title:Binding-triggered transcriptional switches and methods of use thereof
Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Inventor(s): Lim; Wendell A. (San Francisco, CA), Morsut; Leonardo (San Francisco, CA), Roybal; Kole T. (San Francisco, CA), Farlow; Justin Thomas (San Francisco, CA), Toda; Satoshi (San Francisco, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:15/543,220
Patent Claims:see list of patent claims

Details for Patent 10,590,182

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline NUCALA mepolizumab INJECTABLE;SUBCUTANEOUS 761122 001 2019-06-06   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX search
Immunomedics, Inc. TRODELVY sacituzumab govitecan POWDER, FOR SOLUTION 761115 1 2020-04-22   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 search
Immunomedics Inc TRODELVY sacituzumab govitecan-hziy INJECTABLE;INJECTION 761115 001 2020-04-22   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX search
Astrazeneca Ab FASENRA benralizumab INJECTABLE;INJECTION 761070 001 2017-11-14   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX search
Astrazeneca Uk Ltd IMFINZI durvalumab INJECTABLE;INJECTION 761069 001 2017-05-01   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX search
Janssen Biotech TREMFYA guselkumab INJECTABLE;INJECTION 761061 001 2019-01-29   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 001 2018-04-09   Start Trial The Regents of the University of California (Oakland, CA) 2035-02-24 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,590,182

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Express Scripts
Colorcon
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.